Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)
Previous Close
$12.78
52W Range
$6.55 - $12.87
50D Avg
$10.67
200D Avg
$8.85
Market Cap
$1.68B
Avg Vol (3M)
$2.14M
Beta
1.27
Div Yield
-
AUPH Company Profile
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.